Contents
Academy · Research Data, Analytics & AI · Incremental Cost-effectiveness Ratio
The Incremental Cost-Effectiveness Ratio (ICER): Calculation, Thresholds and Comparator Choice
The Incremental Cost-Effectiveness Ratio (ICER): Calculation, Thresholds and Comparator Choice (ICER) is a single fraction, but each of its components reflects a methodological choice, including the comparator, the time horizon and the discount rate. A change in any of these alters the value that decision-makers compare against a threshold. This article explains the calculation, its interpretation and the reporting it requires.
The incremental cost-effectiveness ratio (ICER) is the additional cost of one intervention compared with another, divided by the additional health benefit it produces, expressed as cost per unit of that benefit, most often cost per quality-adjusted life year (QALY) gained in a cost-utility analysis.
Learning objectives
- How the ICER is calculated, and why it is a ratio of differences, not of totals.
- How health technology assessment bodies use cost-effectiveness thresholds to interpret an ICER.
- Why the choice of comparator changes the ICER even when the new intervention itself is unchanged.
- Why an ICER should not be reported without a measure of its uncertainty.
Common misconceptions
- “The ICER is the total cost of a treatment divided by its total benefit.” The ICER is specifically an incremental ratio: the difference in cost between two interventions divided by the difference in their benefit, which is a different calculation from each intervention's absolute cost-per-benefit.
- “A lower ICER is always preferable, irrespective of context.” An ICER is meaningful only relative to a decision-making threshold and to the specific comparator used in its calculation; the same new intervention may produce a different ICER depending on the comparator.
Calculation of the ratio
The ICER is calculated as (cost of new intervention minus cost of comparator) divided by (benefit of new intervention minus benefit of comparator). This incremental framing, rather than each intervention’s absolute cost-per-benefit, is what the UK’s National Institute for Health and Care Excellence (NICE) specifies in its guide to the methods of technology appraisal as the basis for comparing a new intervention’s value against the alternative it would replace in practice, rather than against no intervention or an unrelated baseline.
Cost-effectiveness thresholds
NICE’s methods guide sets out a cost-effectiveness threshold range, used as a reference point for judging whether an ICER represents good value for the health system; an ICER below the threshold is generally considered to represent an efficient use of resources, whereas one above it requires additional justification (such as unmet need or end-of-life considerations) to support funding. The threshold is a decision-making reference, not a scientific constant, and different health systems and technology-assessment bodies set their own.
Effect of comparator choice on the ICER
Because the ICER is explicitly a ratio of differences, the choice of a different comparator changes the result even when the new intervention’s own costs and benefits are held constant; comparison against the current standard of care produces a different ICER from comparison against an older, less effective, cheaper alternative. For this reason, a defensible economic evaluation states its comparator explicitly and justifies it as the realistic alternative that the new intervention would displace, consistent with the broader cost-utility analysis framework discussed in the related article on cost-utility analysis.
Key points
Key points
The ICER is the ratio of the difference in cost to the difference in benefit between a new intervention and a specified comparator, interpreted against a decision-making cost-effectiveness threshold; because it is a ratio of differences, the comparator chosen changes the result even when the new intervention itself is unchanged.
Practical application
Practical application
- The comparator should be stated and justified explicitly. Authors should name the realistic alternative that the new intervention would displace in practice and justify that choice, rather than defaulting to an arbitrary or convenient comparator.
- The ICER should be reported together with its uncertainty. A cost-effectiveness acceptability curve or confidence interval around the ICER should be presented, rather than a single point estimate presented as precise.
- Where a threshold applies, it should be referenced explicitly. If the analysis is intended to inform a decision by a specific health technology assessment body, that body’s published threshold range and the position of the ICER relative to it should be stated.
Frequently asked questions
No; different health systems and assessment bodies set their own thresholds, and some decisions permit funding above the standard threshold for specific considerations such as end-of-life care.
Yes; when a new intervention is both less costly and more effective than the comparator (dominance), the ratio ceases to be informative, and the intervention is typically described as dominant rather than reported as having a negative ICER.
No; the ICER is one input to a funding decision, which can also weigh budget impact, equity considerations, and clinical need alongside cost-effectiveness.
References
- National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. read 10 October 2026. View NICE methods guide (PDF)
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 10). The Incremental Cost-Effectiveness Ratio (ICER): Calculation, Thresholds and Comparator Choice. Pubrica. https://pubrica.com/academy/concepts-definitions/incremental-cost-effectiveness-ratio/
Pubrica Academy. “The Incremental Cost-Effectiveness Ratio (ICER): Calculation, Thresholds and Comparator Choice.” Pubrica, 10 Oct. 2026, pubrica.com/academy/concepts-definitions/incremental-cost-effectiveness-ratio/.
Pubrica Academy (2026) The Incremental Cost-Effectiveness Ratio (ICER): Calculation, Thresholds and Comparator Choice. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/incremental-cost-effectiveness-ratio/ (Accessed: 15 October 2026).
Pubrica Academy. “The Incremental Cost-Effectiveness Ratio (ICER): Calculation, Thresholds and Comparator Choice.” Pubrica. October 10, 2026. https://pubrica.com/academy/concepts-definitions/incremental-cost-effectiveness-ratio/
Pubrica Academy, ‘The Incremental Cost-Effectiveness Ratio (ICER): Calculation, Thresholds and Comparator Choice’ (Pubrica, 10 October 2026) <https://pubrica.com/academy/concepts-definitions/incremental-cost-effectiveness-ratio/> accessed 15 October 2026.
Pubrica Academy. The Incremental Cost-Effectiveness Ratio (ICER): Calculation, Thresholds and Comparator Choice. [Internet]. Pubrica; 2026 Oct 10 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/incremental-cost-effectiveness-ratio/
Pubrica Academy, “The Incremental Cost-Effectiveness Ratio (ICER): Calculation, Thresholds and Comparator Choice,” Pubrica, Oct. 10, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/incremental-cost-effectiveness-ratio/
@misc{incremental_cost_effectiveness_ratio_2026,
author = {{Pubrica Academy}},
title = {The Incremental Cost-Effectiveness Ratio (ICER): Calculation, Thresholds and Comparator Choice},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/incremental-cost-effectiveness-ratio/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
ICER reporting stub
This checklist applies to the reporting of an incremental cost-effectiveness ratio.
New intervention cost: ____ Comparator cost: ____ Incremental cost: ____ New intervention benefit (e.g. QALYs): ____ Comparator benefit: ____ Incremental benefit: ____ ICER (incremental cost / incremental benefit): ____ Relevant threshold, if applicable: ____ Uncertainty presentation (CI / acceptability curve): ____
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s health-economics team calculates and reports ICERs with explicit comparator justification and presentation of uncertainty, structured according to the methods guide of the relevant health technology assessment body.